WO2017046776A3 - Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis - Google Patents

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis Download PDF

Info

Publication number
WO2017046776A3
WO2017046776A3 PCT/IB2016/055559 IB2016055559W WO2017046776A3 WO 2017046776 A3 WO2017046776 A3 WO 2017046776A3 IB 2016055559 W IB2016055559 W IB 2016055559W WO 2017046776 A3 WO2017046776 A3 WO 2017046776A3
Authority
WO
WIPO (PCT)
Prior art keywords
arteritis
treatment
takayasu
prophylaxis
giant cell
Prior art date
Application number
PCT/IB2016/055559
Other languages
French (fr)
Other versions
WO2017046776A2 (en
Inventor
Yue Liu
Patrick Garidel
Andreas Langer
Kenneth Flanagan
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Priority to EP16770571.4A priority Critical patent/EP3350226A2/en
Priority to JP2018513643A priority patent/JP2018530540A/en
Priority to CA2998716A priority patent/CA2998716A1/en
Publication of WO2017046776A2 publication Critical patent/WO2017046776A2/en
Publication of WO2017046776A3 publication Critical patent/WO2017046776A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
PCT/IB2016/055559 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis WO2017046776A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP16770571.4A EP3350226A2 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP2018513643A JP2018530540A (en) 2015-09-16 2016-09-16 Use of anti-MCAM antibodies for the treatment or prevention of giant cell arteritis, polymyalgia rheumatica or Takayasu arteritis
CA2998716A CA2998716A1 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219599P 2015-09-16 2015-09-16
US62/219,599 2015-09-16

Publications (2)

Publication Number Publication Date
WO2017046776A2 WO2017046776A2 (en) 2017-03-23
WO2017046776A3 true WO2017046776A3 (en) 2017-05-04

Family

ID=56990689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055559 WO2017046776A2 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis

Country Status (4)

Country Link
EP (1) EP3350226A2 (en)
JP (1) JP2018530540A (en)
CA (1) CA2998716A1 (en)
WO (1) WO2017046776A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201922795A (en) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 Anti-MCAM antibodies and associated methods of use
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
WO2017208210A1 (en) * 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2020132190A1 (en) * 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217237A1 (en) * 2010-03-02 2011-09-08 Abbott Laboratories Therapeutic dll4 binding proteins
WO2012024187A1 (en) * 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
US20130216556A1 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2013164789A2 (en) * 2012-05-04 2013-11-07 Novartis Ag Antibody formulatoin
WO2013186700A1 (en) * 2012-06-12 2013-12-19 Novartis Ag Antibody formulation
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015061584A1 (en) * 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015136470A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (en) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Strong homologous promoter from hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
KR100444778B1 (en) 1999-02-05 2004-08-18 삼성전자주식회사 Image texture describing method and apparatus
JP2005538706A (en) 2001-07-12 2005-12-22 ジェファーソン フーテ， Super humanized antibody
CA2472154A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Use of antibodies against the muc18 antigen
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc Methods for using anti-muc18 antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
MXPA05005481A (en) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells.
DE10338531A1 (en) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for recloning production cells
KR101235658B1 (en) 2004-11-10 2013-02-21 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Use of flow-cytometric analysis to optimize cell banking strategies for CHO cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PT2099823E (en) 2006-12-01 2014-12-22 Seattle Genetics Inc Variant target binding agents and uses thereof
TWI419902B (en) 2007-03-02 2013-12-21 百靈佳殷格翰製藥公司 Improvement of protein production
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217237A1 (en) * 2010-03-02 2011-09-08 Abbott Laboratories Therapeutic dll4 binding proteins
WO2012024187A1 (en) * 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
US20130216556A1 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2013164789A2 (en) * 2012-05-04 2013-11-07 Novartis Ag Antibody formulatoin
WO2013186700A1 (en) * 2012-06-12 2013-12-19 Novartis Ag Antibody formulation
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015061584A1 (en) * 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015136470A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LORICERA JAVIER ET AL: "Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients", SEMINARS IN ARTHRITIS AND RHEUMATISM, vol. 44, no. 6, 27 December 2014 (2014-12-27), pages 717 - 723, XP029229325, ISSN: 0049-0172, DOI: 10.1016/J.SEMARTHRIT.2014.12.005 *
YING ZHANG ET AL: "Generation and Characterization of a Panel of Monoclonal Antibodies Against Distinct Epitopes of Human CD146", HYBRIDOMA, vol. 27, no. 5, 1 October 2008 (2008-10-01), pages 345 - 352, XP055155690, ISSN: 1554-0014, DOI: 10.1089/hyb.2008.0034 *
ZHENG C ET AL: "Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 41, no. 11, 1 November 2009 (2009-11-01), pages 2163 - 2172, XP026644025, ISSN: 1357-2725, [retrieved on 20090405], DOI: 10.1016/J.BIOCEL.2009.03.014 *

Also Published As

Publication number Publication date
EP3350226A2 (en) 2018-07-25
WO2017046776A2 (en) 2017-03-23
JP2018530540A (en) 2018-10-18
CA2998716A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
WO2017046774A3 (en) Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A3 (en) Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12016501760A1 (en) Anti-mcam antibodies and associated methods of use
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2023014569A (en) Anti-sirp alpha antibodies.
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
PH12017502358A1 (en) Factor xi antibodies and methods of use
WO2017030823A3 (en) Anti-tigit antibodies
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2017062619A3 (en) Combination therapy for the treatment of cancer
MX2020001555A (en) Glycan therapeutics and related methods thereof.
WO2015157629A3 (en) Antibodies, pharmaceutical compositions and uses thereof
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2019007347A (en) Anti-cd3 antibody, and molecule containing said antibody.
WO2019142149A3 (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
WO2017049038A3 (en) Anti-cd115 antibodies
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
WO2017062615A3 (en) Combination therapy for the treatment of cancer
MX2021005085A (en) Antibody formulation.
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
WO2018087143A3 (en) Anti-pd-1 antibodies
MX2020002802A (en) Heavy chain antibodies binding to ectoenzymes.
MX2018009948A (en) Oritavancin formulations.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770571

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2998716

Country of ref document: CA

Ref document number: 2018513643

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016770571

Country of ref document: EP